Ulcer classification and current appearance
Grade, depth, size, duration, drainage, necrosis, exposed tendon or bone and recent photo sequence are organized in one clinical timeline.
A structured file review for complex diabetic foot ulcers, organized around wound depth, infection status, vascular supply, diabetes control, previous wound-care response and whether a Heberprot-P® discussion may be clinically appropriate.
Diabetic foot ulcer evaluation is not a simple photo review. The physician needs to understand whether the wound is ischemic, neuropathic, infected, surgically managed, improving, stalled or worsening. The file is prepared so the clinical question is realistic and the patient is not pushed toward international coordination before urgent local care is addressed.
Grade, depth, size, duration, drainage, necrosis, exposed tendon or bone and recent photo sequence are organized in one clinical timeline.
Doppler, ABI, angiography, vascular surgery notes or revascularization history are reviewed because blood supply can determine whether advanced wound therapies are safe or realistic.
Culture results, antibiotics, inflammatory markers, imaging for bone infection and debridement history are checked before any treatment or travel discussion.
HbA1c, insulin or medication use, kidney function, nutrition, neuropathy and comorbidities help frame healing capacity and safety.
Dressings, off-loading, negative-pressure therapy, debridement, grafts, antibiotics and prior specialist opinions are summarized chronologically.
The file should ask whether additional physician review is meaningful, what is missing and whether a Heberprot-P® discussion is medically relevant.
The page is intentionally structured around clinical decision factors, not around promotional claims. The aim is to make the file safer, clearer and easier to review.
Uncontrolled infection, critical ischemia or acute limb threat may require immediate local hospital care before coordination continues.
Heberprot-P® is treated as a physician-review topic for selected diabetic foot ulcer contexts, not as a universal solution or guaranteed outcome.
Images are most useful when paired with dates, measurements, wound-care notes and information about pain, discharge, odor and fever.
The patient should receive a clear explanation of missing documents, review limits and practical next steps before payment or travel logistics.
A wound-care file must be complete enough to let the physician understand local risk, previous care and current urgency. These documents usually reduce unnecessary back-and-forth.
The page does not present a procedure or travel plan as automatically suitable. Any Cuba-related discussion remains conditional on physician review of the current file.
The patient should continue appropriate local care while the file is being organized, especially when symptoms are active or worsening.
Treatment names may be part of the medical context, but suitability, contraindications, dosing and monitoring must be determined by physicians.
The first decision is whether the file is complete enough for a responsible written response. Logistics come only after clinical clarity.
This treatment does not replace standard wound care; it is added to it.
Heberprot-P was developed at the Center for Genetic Engineering and Biotechnology (CIGB) in Cuba and contains recombinant human epidermal growth factor (rhEGF). In people with diabetes, reduced growth-factor signalling and receptor density in wound tissue contribute to stalled healing. The aim of treatment is to deliver that signal directly into the wound bed and restart the repair process.
It is not a cream or a dressing: it is given as intralesional injections into the wound base and edges, in a clinical setting and by trained staff. Published protocols schedule three applications per week, stopping when granulation tissue is adequate, with total duration in most patients not exceeding eight weeks. The most frequently reported side effects are pain and burning at the injection site, shivering, fever and nausea.
The manufacturer and treating centres report high rates of amputation avoidance in large series. Those reports are valuable, but the size and design of independent randomised studies do not support a firm promise of avoiding amputation. Outcome is determined above all by adequate circulation, infection control, debridement, offloading and glycaemic management.
Where critical ischaemia exists, restoring blood flow comes first; granulation tissue will not form without adequate perfusion.
Spreading infection or suspected osteomyelitis must be treated first; application during active infection does not change the outcome.
Removing pressure from the wound with suitable footwear, a cast or a device is a basic condition for healing, independent of any drug.
International coordination should never delay emergency or necessary local care. If any of the following are present, the patient should be assessed locally first.
No. This page explains how the file is prepared. Suitability can only be determined by licensed physicians after reviewing the complete wound, vascular, infection and diabetes context.
Usually no. Photos are important, but wound history, infection status, vascular supply and diabetes control are essential for a meaningful review.
No. Acute infection, ischemia, sepsis concern or rapidly worsening wounds must be assessed locally first.
Cuba Health Assist organizes documents, translations where needed, communication with the review pathway and written next-step logistics.
Travel should not be the first decision. The file should be reviewed first so expectations, safety and missing documents are clear.
A coordinator will organize the medical information and guide the next step according to specialist review. The process is designed to be transparent, clinically cautious and written.